TY - JOUR
T1 - Digestive Neuroendocrine Neoplasms (NEN)
T2 - French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR)
AU - Thésaurus National de Cancérologie Digestive (TNCD)
AU - de Mestier, Louis
AU - Lepage, Come
AU - Baudin, Eric
AU - Coriat, Romain
AU - Courbon, Frédéric
AU - Couvelard, Anne
AU - Do Cao, Christine
AU - Frampas, Eric
AU - Gaujoux, Sébastien
AU - Gincul, Rodica
AU - Goudet, Pierre
AU - Lombard-Bohas, Catherine
AU - Poncet, Gilles
AU - Smith, Denis
AU - Ruszniewski, Philippe
AU - Lecomte, Thierry
AU - Bouché, Olivier
AU - Walter, Thomas
AU - Cadiot, Guillaume
N1 - Publisher Copyright:
© 2020 Editrice Gastroenterologica Italiana S.r.l.
PY - 2020/5/1
Y1 - 2020/5/1
N2 - Introduction: This document is a summary of the French Intergroup guidelines regarding the management of digestive neuroendocrine neoplasms (NEN) published in February 2020 (www.tncd.org). Methods: All French medical societies involved in the management of NEN took part in this work. Recommendations were graded into four categories (A, B, C or D), according to the level of evidence found in the literature until May 2019. Results: The management of NEN is challenging because of their heterogeneity and the increasing complexity of diagnostic and therapeutic procedures. Pathological analysis is required for their diagnostic and prognostic characterization, which mainly relies on differentiation, grade and stage. The two main emergency situations are functioning syndromes and poorly-differentiated carcinoma. Chromogranin A is the main biochemical marker of NET, although of limited clinical interest. Initial characterization relies on morphological and isotopic imaging. The treatment of localized NET relies on watchful follow-up and local or surgical resection depending on its supposed aggressiveness. Treatment options for metastatic disease include surgery, somatostatin analogues, chemotherapy, targeted therapies, organ-driven locoregional therapies and peptide-receptor radionuclide therapy. As specific predictive factors of treatment efficacy are yet to be identified and head-to-head comparisons have not or only rarely been performed, the therapeutic strategy currently depends on prognostic factors. Cumulative toxicity and the impact of treatment on quality of life must be considered since survival is relatively long in most patients with NET. Conclusion: These guidelines are proposed to achieve the most beneficial therapeutic strategy in clinical practice as the therapeutic landscape of NEN is becoming ever more complex. These recommendations are permanently being reviewed.
AB - Introduction: This document is a summary of the French Intergroup guidelines regarding the management of digestive neuroendocrine neoplasms (NEN) published in February 2020 (www.tncd.org). Methods: All French medical societies involved in the management of NEN took part in this work. Recommendations were graded into four categories (A, B, C or D), according to the level of evidence found in the literature until May 2019. Results: The management of NEN is challenging because of their heterogeneity and the increasing complexity of diagnostic and therapeutic procedures. Pathological analysis is required for their diagnostic and prognostic characterization, which mainly relies on differentiation, grade and stage. The two main emergency situations are functioning syndromes and poorly-differentiated carcinoma. Chromogranin A is the main biochemical marker of NET, although of limited clinical interest. Initial characterization relies on morphological and isotopic imaging. The treatment of localized NET relies on watchful follow-up and local or surgical resection depending on its supposed aggressiveness. Treatment options for metastatic disease include surgery, somatostatin analogues, chemotherapy, targeted therapies, organ-driven locoregional therapies and peptide-receptor radionuclide therapy. As specific predictive factors of treatment efficacy are yet to be identified and head-to-head comparisons have not or only rarely been performed, the therapeutic strategy currently depends on prognostic factors. Cumulative toxicity and the impact of treatment on quality of life must be considered since survival is relatively long in most patients with NET. Conclusion: These guidelines are proposed to achieve the most beneficial therapeutic strategy in clinical practice as the therapeutic landscape of NEN is becoming ever more complex. These recommendations are permanently being reviewed.
KW - Carcinoid
KW - Diagnosis
KW - French clinical practice guidelines
KW - Neuroendocrine neoplasms
KW - Prognosis
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=85083896233&partnerID=8YFLogxK
U2 - 10.1016/j.dld.2020.02.011
DO - 10.1016/j.dld.2020.02.011
M3 - Article
C2 - 32234416
AN - SCOPUS:85083896233
SN - 1590-8658
VL - 52
SP - 473
EP - 492
JO - Digestive and Liver Disease
JF - Digestive and Liver Disease
IS - 5
ER -